 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes BACTRIM increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does BACTRIM increase the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"BACTRIM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: BACTRIM: adverse_reactions: Hematologic: Agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia, megaloblastic anemia, hypoprothrombinemia, [0m
[31mmethemoglobinemia, eosinophilia, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura. BACTRIM: adverse_reactions: Allergic Reactions: Stevens-Johnson syndrome, toxic epidermal [0m
[31mnecrolysis, anaphylaxis, allergic myocarditis, erythema multiforme, exfoliative dermatitis, angioedema, drug fever, chills, Henoch-Schoenlein purpura, serum sickness-like syndrome, generalized [0m
[31mallergic reactions, generalized skin eruptions, photosensitivity, conjunctival and scleral injection, pruritus, urticaria, rash, periarteritis nodosa, systemic lupus erythematosus, drug reaction with [0m
[31meosinophilia and systemic symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, acute generalized erythematous pustulosis [0m[1;31m([0m[31mAGEP[0m[1;31m)[0m[31m, and acute febrile neutrophilic dermatosis [0m[1;31m([0m[31mAFND[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. BACTRIM: adverse_reactions: [0m
[31mGastrointestinal: Hepatitis [0m[1;31m([0m[31mincluding cholestatic jaundice and hepatic necrosis[0m[1;31m)[0m[31m, elevation of serum transaminase and bilirubin, pseudomembranous enterocolitis, pancreatitis, stomatitis, glossitis, [0m
[31mnausea, emesis, abdominal pain, diarrhea, anorexia. Genitourinary: Renal failure, interstitial nephritis, BUN and serum creatinine elevation, renal insufficiency, oliguria and anuria, crystalluria and[0m
[31mnephrotoxicity in association with cyclosporine. Metabolic and Nutritional: Hyperkalemia, hyponatremia [0m[1;31m([0m[31msee PRECAUTIONS: Electrolyte Abnormalities [0m[1;31m)[0m[31m, metabolic acidosis. Neurologic: Aseptic [0m
[31mmeningitis, convulsions, peripheral neuritis, ataxia, vertigo, tinnitus, headache. Psychiatric: Hallucinations, depression, apathy, nervousness. BACTRIM: adverse_reactions: Endocrine: The sulfonamides[0m
[31mbear certain chemical similarities to some goitrogens, diuretics [0m[1;31m([0m[31macetazolamide and the thiazides[0m[1;31m)[0m[31m and oral hypoglycemic agents. Cross-sensitivity may exist with these agents. Diuresis and [0m
[31mhypoglycemia have occurred. Musculoskeletal: Arthralgia, myalgia, rhabdomyolysis. Respiratory: Cough, shortness of breath and pulmonary infiltrates, acute eosinophilic pneumonia, acute and delayed [0m
[31mlung injury, interstitial lung disease, acute respiratory failure [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Cardiovascular System: QT prolongation resulting in ventricular tachycardia and torsades de pointes , circulatory [0m
[31mshock [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m . Miscellaneous: Weakness, fatigue, insomnia.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: drug_interactions_table: This interaction should be kept in mind when BACTRIM is given to patients already on anticoagulant therapy, and the coagulation time should be [0m
[31mreassessed.[0m[1;31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Phenytoin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Monitor serum phenytoin levels<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>BACTRIM may inhibit the hepatic metabolism of phenytoin [0m[1;31m([0m[31ma CYP2C9 [0m
[31msubstrate[0m[1;31m)[0m[31m. BACTRIM, given at a common clinical dosage, increased the phenytoin half-life by [0m[1;31m39[0m[31m% and decreased the phenytoin metabolic clearance rate by [0m[1;31m27[0m[31m%. BACTRIM: drug_interactions_table: [0m
[31m.<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Methotrexate<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid concurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule[0m
[31m"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate [0m
[31mconcentrations. BACTRIM: drug_interactions_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Cyclosporine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m [0m
[31mLrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid concurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>There have been reports of marked but reversible [0m
[31mnephrotoxicity with coadministration of BACTRIM and cyclosporine in renal transplant recipients. BACTRIM: drug_interactions_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Digoxin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Monitor serum digoxin levels<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule [0m
[31mBotrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. BACTRIM: drug_interactions_table: [0m
[31mparagraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Indomethacin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid [0m
[31mconcurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph[0m[1;31m>[0m[31mIncreased sulfamethoxazole blood levels may occur in patients who are also receiving indomethacin.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: drug_interactions: Cyclosporine Avoid concurrent use There have been reports of marked but reversible nephrotoxicity with coadministration of BACTRIM and cyclosporine in renal [0m
[31mtransplant recipients. Digoxin Monitor serum digoxin levels Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Indomethacin Avoid concurrent use[0m
[31mIncreased sulfamethoxazole blood levels may occur in patients who are also receiving indomethacin. Pyrimethamine Avoid concurrent use Occasional reports suggest that patients receiving pyrimethamine [0m
[31mas malaria prophylaxis in doses exceeding [0m[1;31m25[0m[31m mg weekly may develop megaloblastic anemia if BACTRIM is prescribed. Tricyclic Antidepressants [0m[1;31m([0m[31mTCAs[0m[1;31m)[0m[31m Monitor therapeutic response and adjust dose of TCA [0m
[31maccordingly The efficacy of tricyclic antidepressants can decrease when coadministered with BACTRIM. BACTRIM: drug_interactions: Oral Hypoglycemics Monitor blood glucose more frequently Like other [0m
[31msulfonamide-containing drugs, BACTRIM potentiates the effect of oral hypoglycemic that are metabolized by CYP2C8 [0m[1;31m([0m[31me.g., pioglitazone, repaglinide, and rosiglitazone[0m[1;31m)[0m[31m or CYP2C9 [0m[1;31m([0m[31me.g., glipizide and [0m
[31mglyburide[0m[1;31m)[0m[31m or eliminated renally via OCT2 [0m[1;31m([0m[31me.g., metformin[0m[1;31m)[0m[31m. Additional monitoring of blood glucose may be warranted. Amantadine Avoid concurrent use In the literature, a single case of toxic delirium[0m
[31mhas been reported after concomitant intake of BACTRIM and amantadine [0m[1;31m([0m[31man OCT2 substrate[0m[1;31m)[0m[31m. Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported. BACTRIM: [0m
[31mdrug_interactions: Angiotensin Converting Enzyme Inhibitors Avoid concurrent use In the literature, three cases of hyperkalemia in elderly patients have been reported after concomitant intake of [0m
[31mBACTRIM and an angiotensin converting enzyme inhibitor. [0m[1;31m5[0m[31m,[0m[1;31m6[0m[31m Zidovudine Monitor for hematologic toxicity Zidovudine and BACTRIM are known to induce hematological abnormalities. Hence, there is [0m
[31mpotential for an additive myelotoxicity when coadministered. [0m[1;31m7[0m[31m Dofetilide Concurrent administration is contraindicated Elevated plasma concentrations of dofetilide have been reported following [0m
[31mconcurrent administration of trimethoprim and dofetilide. Increased plasma concentrations of dofetilide may cause serious ventricular arrhythmias associated with QT interval prolongation, including [0m
[31mtorsade de pointes . BACTRIM: drug_interactions: [0m[1;31m8[0m[31m,[0m[1;31m9[0m[31m Procainamide Closely monitor for clinical and ECG signs of procainamide toxicity and/or procainamide plasma concentration if available Trimethoprim[0m
[31mincreases the plasma concentrations of procainamide and its active N-acetyl metabolite [0m[1;31m([0m[31mNAPA[0m[1;31m)[0m[31m when trimethoprim and procainamide are coadministered. The increased procainamide and NAPA plasma [0m
[31mconcentrations that resulted from the pharmacokinetic interaction with trimethoprim are associated with further prolongation of the QTc interval.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: precautions: PRECAUTIONS Development of Drug Resistant Bacteria Prescribing Bactrim [0m[1;31m([0m[31msulfamethoxazole and trimethoprim[0m[1;31m)[0m[31m tablets in the absence of a proven or strongly suspected [0m
[31mbacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Folate Deficiency Avoid use of [0m
[31mBACTRIM in patients with impaired renal or hepatic function, in those with possible folate deficiency [0m[1;31m([0m[31me.g., the elderly, chronic alcoholics, patients receiving anticonvulsant therapy, patients with [0m
[31mmalabsorption syndrome, and patients in malnutrition states[0m[1;31m)[0m[31m and in those with severe allergies or bronchial asthma. Hematological changes indicative of folic acid deficiency may occur in elderly [0m
[31mpatients or in patients with preexisting folic acid deficiency or kidney failure. These effects are reversible by folinic acid therapy [0m[1;31m([0m[31msee PRECAUTIONS, Geriatric Use [0m[1;31m)[0m[31m. BACTRIM: precautions: [0m
[31mHemolysis In glucose-[0m[1;31m6[0m[31m-phosphate dehydrogenase deficient individuals, hemolysis may occur. This reaction is frequently dose-related. Hypoglycemia Cases of hypoglycemia in non-diabetic patients treated[0m
[31mwith BACTRIM are seen rarely, usually occurring after a few days of therapy. Patients with renal dysfunction, liver disease, malnutrition or those receiving high doses of BACTRIM are particularly at [0m
[31mrisk. Impaired Phenylalanine Metabolism The trimethoprim component of BACTRIM has been noted to impair phenylalanine metabolism, but this is of no significance in phenylketonuric patients on [0m
[31mappropriate dietary restriction. Porphyria and Hypothyroidism Like other drugs containing sulfonamides, BACTRIM can precipitate porphyria crisis and hypothyroidism. Avoid use of BACTRIM in patients [0m
[31mwith porphyria or thyroid dysfunction. BACTRIM: precautions: Potential Risk in the Treatment of Pneumocystis jirovecii Pneumonia in Patients with Acquired Immunodeficiency Syndrome [0m[1;31m([0m[31mAIDS[0m[1;31m)[0m[31m AIDS [0m
[31mpatients may not tolerate or respond to BACTRIM in the same manner as non-AIDS patients. The incidence of adverse reactions, particularly rash, fever, leukopenia and elevated aminotransferase [0m
[1;31m([0m[31mtransaminase[0m[1;31m)[0m[31m values, with BACTRIM therapy in AIDS patients who are being treated for P. jirovecii pneumonia has been reported to be increased compared with the incidence normally associated with the[0m
[31muse of BACTRIM in non-AIDS patients. If a patient develops skin rash, fever, leukopenia or any sign of adverse reaction, reevaluate benefit-risk of continuing therapy or re-challenge with BACTRIM [0m[1;31m([0m[31msee[0m
[31mWARNINGS [0m[1;31m)[0m[31m. Avoid coadministration of BACTRIM and leucovorin during treatment of P. jirovecii pneumonia [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: references: REFERENCES [0m[1;31m1[0m[31m. Kremers P, Duvivier J, Heusghem C. Pharmacokinetic Studies of Co-Trimoxazole in Man after Single and Repeated Doses. J Clin Pharmacol . Feb-Mar [0m[1;31m1974[0m[31m; [0m
[1;31m14:112[0m[31m–[0m[1;31m117[0m[31m. [0m[1;31m2[0m[31m. Kaplan SA, et al. Pharmacokinetic Profile of Trimethoprim-Sulfamethoxazole in Man. J Infect Dis . Nov [0m[1;31m1973[0m[31m; [0m[1;31m128[0m[31m [0m[1;31m([0m[31mSuppl[0m[1;31m)[0m[31m: S547–S555. [0m[1;31m3[0m[31m. Varoquaux O, et al. Pharmacokinetics of the [0m
[31mtrimethoprim-sulfamethoxazole combination in the elderly. Br J Clin Pharmacol . [0m[1;31m1985[0m[31m; [0m[1;31m20:575[0m[31m–[0m[1;31m581[0m[31m. [0m[1;31m4[0m[31m. Safrin S, Lee BL, Sande MA. BACTRIM: references: Adjunctive folinic acid with [0m
[31mtrimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis . [0m[1;31m1994[0m[31m Oct;[0m[1;31m170[0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m:[0m[1;31m912[0m[31m–[0m[1;31m7[0m[31m. [0m[1;31m5[0m[31m. [0m
[31mMarinella Mark A. [0m[1;31m1999[0m[31m. Trimethoprim-induced hyperkalemia: An analysis of reported cases. Gerontol . [0m[1;31m45:209[0m[31m–[0m[1;31m212[0m[31m. [0m[1;31m6[0m[31m. Margassery, S. and B. Bastani. [0m[1;31m2002[0m[31m. Life threatening hyperkalemia and acidosis [0m
[31msecondary to trimethoprim-sulfamethoxazole treatment. J. Nephrol . [0m[1;31m14:410[0m[31m–[0m[1;31m414[0m[31m. [0m[1;31m7[0m[31m. Moh R, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with [0m
[31mcotrimoxazole in Côte d’Ivoire. BACTRIM: references: Antivir Ther . [0m[1;31m2005[0m[31m;[0m[1;31m10[0m[1;31m([0m[1;31m5[0m[1;31m)[0m[31m:[0m[1;31m615[0m[31m-[0m[1;31m24[0m[31m. [0m[1;31m8[0m[31m. Al-Khatib SM, LaPointe N, Kramer JM, Califf RM. What Clinicians Should Know About the QT Interval. JAMA . [0m
[1;31m2003[0m[31m;[0m[1;31m289[0m[1;31m([0m[1;31m16[0m[1;31m)[0m[31m:[0m[1;31m2120[0m[31m-[0m[1;31m2127[0m[31m. [0m[1;31m9[0m[31m. Boyer EW, Stork C, Wang RY. Review: The Pharmacology and Toxicology of Dofetilide. Int J Med Toxicol. [0m[1;31m2001[0m[31m;[0m[1;31m4[0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m:[0m[1;31m16[0m[31m. [0m[1;31m10[0m[31m. Kosoglou T, Rocci ML Jr, Vlasses PH. Trimethoprim [0m
[31malters the disposition of procainamide and N- acetylprocainamide. Clin Pharmacol Ther . Oct [0m[1;31m1988[0m[31m;[0m[1;31m44[0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m:[0m[1;31m467[0m[31m-[0m[1;31m77[0m[31m. [0m[1;31m11[0m[31m. Brumfitt W, Pursell R. Trimethoprim/Sulfamethoxazole in the Treatment of Bacteriuria [0m
[31min Women. BACTRIM: references: J Infect Dis . Nov [0m[1;31m1973[0m[31m; [0m[1;31m128[0m[31m [0m[1;31m([0m[31mSuppl[0m[1;31m)[0m[31m: S657–S663. [0m[1;31m12[0m[31m. Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med . [0m[1;31m1992[0m[31m; [0m[1;31m327[0m[31m: [0m[1;31m1853[0m[31m–[0m[1;31m1880[0m[31m. [0m[1;31m13[0m[31m. [0m
[31mRecommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR. [0m[1;31m1992[0m[31m; [0m[1;31m41[0m[1;31m([0m[31mRR–[0m[1;31m4[0m[1;31m)[0m[31m:[0m[1;31m1[0m[31m–[0m[1;31m11[0m[31m. [0m[1;31m14[0m[31m. CDC Guidelines for [0m
[31mprophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. MMWR . [0m[1;31m1991[0m[31m; [0m[1;31m40[0m[1;31m([0m[31mRR–[0m[1;31m2[0m[1;31m)[0m[31m:[0m[1;31m1[0m[31m–[0m[1;31m13[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: teratogenic_effects: Teratogenic Effects Human Data While there are no large prospective, well controlled studies in pregnant women and their babies, some retrospective epidemiologic[0m
[31mstudies suggest an association between first trimester exposure to sulfamethoxazole and trimethoprim with an increased risk of congenital malformations, particularly neural tube defects, [0m
[31mcardiovascular abnormalities, urinary tract defects, oral clefts, and club foot. These studies, however, were limited by the small number of exposed cases and the lack of adjustment for multiple [0m
[31mstatistical comparisons and confounders. These studies are further limited by recall, selection, and information biases, and by limited generalizability of their findings. Lastly, outcome measures [0m
[31mvaried between studies, limiting cross-study comparisons. Alternatively, other epidemiologic studies did not detect statistically significant associations between sulfamethoxazole and trimethoprim [0m
[31mexposure and specific malformations. BACTRIM: teratogenic_effects: Animal Data In rats, oral doses of either [0m[1;31m533[0m[31m mg/kg sulfamethoxazole or [0m[1;31m200[0m[31m mg/kg trimethoprim produced teratologic effects [0m
[31mmanifested mainly as cleft palates. These doses are approximately [0m[1;31m5[0m[31m and [0m[1;31m6[0m[31m times the recommended human total daily dose on a body surface area basis. In two studies in rats, no teratology was observed [0m
[31mwhen [0m[1;31m512[0m[31m mg/kg of sulfamethoxazole was used in combination with [0m[1;31m128[0m[31m mg/kg of trimethoprim. In some rabbit studies, an overall increase in fetal loss [0m[1;31m([0m[31mdead and resorbed conceptuses[0m[1;31m)[0m[31m was associated with[0m
[31mdoses of trimethoprim [0m[1;31m6[0m[31m times the human therapeutic dose based on body surface area.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: laboratory_tests: Laboratory Tests Complete blood counts and clinical chemistry testing should be done frequently in patients receiving BACTRIM. Perform urinalyses with careful [0m
[31mmicroscopic examination and renal function tests during therapy, particularly for those patients with impaired renal function. Discontinue BACTRIM if a significant electrolyte abnormality, renal [0m
[31minsufficiency or reduction in the count of any formed blood element is noted.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: geriatric_use: Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger [0m
[31msubjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible folate [0m
[31mdeficiency, or concomitant use of other drugs. Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee WARNINGS and ADVERSE REACTIONS sections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or [0m
[31mwithout purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased [0m
[31mincidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Serum digoxin levels should be [0m
[31mmonitored. BACTRIM: geriatric_use: Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage [0m
[31madjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m
[31msection[0m[1;31m)[0m[31m. The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency or when given [0m
[31mconcomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of BACTRIM [0m
[31mtreatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Bactrim DS Tablets contain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet.[0m
[31mBACTRIM: geriatric_use: Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher [0m
[31mand mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: BACTRIM can increase the risk of renal failure. The adverse reactions section of the BACTRIM label lists renal failure, interstitial nephritis, BUN and serum creatinine elevation, renal [0m
[32minsufficiency, oliguria and anuria, crystalluria, and nephrotoxicity in association with cyclosporine as potential genitourinary adverse reactions. Additionally, there have been reports of marked but [0m
[32mreversible nephrotoxicity with the coadministration of BACTRIM and cyclosporine in renal transplant recipients.[0m

[32mSOURCE: BACTRIM label[0m
[32mEXTRACT_START_END: Genitourinary: Renal failure, interstitial nephritis [0m[32m...[0m[32m nephrotoxicity in association with cyclosporine.[0m
*[1m([0morchestrator-renal failure-BACTRIM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: BACTRIM can increase the risk of renal failure. The adverse [0m
[34mreactions section of the BACTRIM label lists renal failure, interstitial nephritis, BUN and serum creatinine elevation, renal insufficiency, oliguria and anuria, crystalluria, and nephrotoxicity in [0m
[34massociation with cyclosporine as potential genitourinary adverse reactions. Additionally, there have been reports of marked but reversible nephrotoxicity with the coadministration of BACTRIM and [0m
[34mcyclosporine in renal transplant recipients.[0m

[34mSOURCE: BACTRIM label[0m
[34mEXTRACT_START_END: Genitourinary: Renal failure, interstitial nephritis [0m[34m...[0m[34m nephrotoxicity in association with cyclosporine.[0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if BACTRIM increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that BACTRIM can increase the risk of renal failure. The adverse reactions section of the BACTRIM label lists renal failure and other related renal issues as potential [0m
[32mgenitourinary adverse reactions. Additionally, there have been reports of marked but reversible nephrotoxicity with the coadministration of BACTRIM and cyclosporine in renal transplant recipients."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"BACTRIM can increase the risk of renal failure."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does BACTRIM increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if BACTRIM increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that BACTRIM can increase the risk of renal failure. The adverse reactions section of the BACTRIM label lists renal failure and other related renal issues as potential [0m
[34mgenitourinary adverse reactions. Additionally, there have been reports of marked but reversible nephrotoxicity with the coadministration of BACTRIM and cyclosporine in renal transplant recipients."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"BACTRIM can increase the risk of renal failure."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does BACTRIM increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if BACTRIM increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler responded that BACTRIM can increase the risk of renal failure. The adverse reactions section of the BACTRIM label lists renal failure and other related renal issues as potential [0m
[31mgenitourinary adverse reactions. Additionally, there have been reports of marked but reversible nephrotoxicity with the coadministration of BACTRIM and cyclosporine in renal transplant recipients.[0m
[31m        -----[0m
[31m        Final answer: BACTRIM can increase the risk of renal failure.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-BACTRIM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mBACTRIM can increase the risk of renal failure. This information comes from the adverse reactions section of the BACTRIM label, which lists renal failure and other related renal issues as potential [0m
[32mgenitourinary adverse reactions. Additionally, there have been reports of marked but reversible nephrotoxicity with the coadministration of BACTRIM and cyclosporine in renal transplant recipients.[0m
